Director, Global Commercial Strategy – GI

Johnson & Johnson Innovative Medicine•Horsham, PA

1d•Hybrid

About The Position

We are searching for the best talent for a Director, Global Commercial Strategy – GI located in Horsham, PA or Spring House, PA. About Immunology Our expertise in Innovative Medicine is informed and inspired by patients, whose insights fuel our science-based advancements. Visionaries like you work on teams that save lives by developing the medicines of tomorrow. Our Immunology team leads in the development of transformational medicines for immunological disorders and illnesses. You can influence where medicine is going by restoring health to millions of people living with immune diseases. Join us in developing treatments, finding cures, and pioneering the path from lab to life while championing patients every step of the way. Learn more at https://www.jnj.com/innovative-medicine. Purpose: The Director, Global Commercial Strategy – GI will drive integrated commercial strategy across early discovery through late-stage development assets within the GI portfolio. This role partners closely with GCSO, R&D, Medical Affairs, Market Access, Business Development, and regional commercial teams to embed commercial input early, shape development decisions, advance launch readiness, and maximize long-term asset and portfolio value. This position reports to Sophie Shen, Senior Director, Global Commercial Strategy – Gastroenterology (GI).

Requirements

A Bachelor’s degree is required.
10+ years of progressive experience in pharmaceutical, biotech, or healthcare commercial strategy, marketing, business development, market access, medical affairs, R&D strategy, or related functions
Demonstrated experience developing commercial strategy for pipeline, early development, late-stage, and/or launch assets, ideally in immunology, gastroenterology, or specialty medicine
Strong understanding of drug development, clinical trial design, endpoints, regulatory considerations, evidence generation, market access, and global commercialization requirements
Strong strategic thinking, analytical rigor, and business acumen, with ability to translate scientific, clinical, competitive, and market insights into clear commercial implications and actionable recommendations
Excellent written and verbal communication skills, including ability to develop executive-ready narratives, synthesize complex information, and present recommendations to senior leadership
Demonstrated leadership behaviors consistent with Our Credo and J&J leadership expectations, including accountability, collaboration, inclusion, agility, and enterprise mindset

Nice To Haves

An advanced degree preferred, including MBA, PharmD, PhD, MD, or related scientific/business discipline.
Proven ability to shape target product profiles, value propositions, asset positioning, competitive strategy, and investment recommendations in partnership with R&D, Medical Affairs, Market Access, GCI, regional teams, and Business Development
Experience leading complex, global, cross-functional initiatives in a matrix environment, with the ability to influence senior stakeholders without direct authority

Responsibilities

Serve as the commercial lead for early-stage Compound Development Teams (CDTs), embedding commercial strategy from discovery through proof-of-concept to ensure development plans are aligned with DAS roadmap and long-term portfolio value
Translate the DAS roadmap into actionable asset-level strategies by defining priority disease spaces, patient segments, clinical value drivers, differentiation requirements, and evidence needs across the early pipeline
Shape target product profiles (TPPs), indication sequencing, competitive positioning, and go/no-go criteria to support timely investment decisions and maximize probability of technical, regulatory, and commercial success
Provide commercial input into clinical trial design, endpoint selection, comparator strategy, patient enrichment, line-of-therapy positioning, and label-enabling evidence generation for priority GI assets
Drive portfolio prioritization across internal programs and external innovation opportunities, integrating unmet need, competitive intensity, mechanism differentiation, market access feasibility, and revenue potential
Partner with Business Development, R&D, Medical Affairs, GCI, Market Access, and regions to evaluate external assets, combination strategies, and white-space opportunities that can accelerate or strengthen execution of the GI roadmap
Develop executive-ready recommendations for governance forums, including CDT, DAS, IPC, and portfolio reviews
Partner with late-development program teams to translate asset strategy into launch-ready commercial plans, including indication prioritization, evidence gaps, competitive readiness, positioning, and value proposition
Lead commercial workstreams for late-stage assets, ensuring the launch strategy is grounded with solid forecasting from regional input
Shape pre-launch planning across target product profile refinement, launch sequencing, brand positioning, evidence generation, stakeholder engagement, and readiness milestones
Partner with cross-functional teams to pressure-test launch assumptions, identify key risks and opportunities, and develop clear recommendations for governance and investment decisions
Lead competitive strategy and differentiation planning
Partner with R&D and Medical Affairs on scientific narrative and evidence generation
Collaborate with Market Access on value and reimbursement strategies for early stage assets
Generate actionable insights with GCI to inform strategy